세계의 백신 수탁 제조 시장 : 유형별, 기능별, 용도별 - 예측(2025-2030년)

The Vaccine Contract Manufacturing Market was valued at USD 5.06 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 9.21%, to USD 9.39 billion by 2030.

The Vaccine Contract Manufacturing market primarily involves the outsourcing of vaccine production processes to third-party manufacturers who hold specialized capabilities in handling large-scale production, regulatory compliance, and advanced technology platforms. This sector is increasingly crucial due to escalating global health challenges, which include the emergence of new infectious diseases and the need for rapid vaccine deployment. The necessity of vaccine contract manufacturing arises from the growing demand for vaccines, especially during pandemics, where speed and capacity become critical bottlenecks. Applications span across various therapeutic areas including preventative vaccines for infectious diseases, oncology, and through innovative modalities like mRNA technology. End-users in this realm primarily include pharmaceutical companies, healthcare providers, and government agencies.

Market growth is propelled by several factors, including the globalization of pharmaceutical supply chains, technological advancements in vaccine production methods, and increasing healthcare expenditure. Moreover, the rise in awareness regarding disease prevention and the emphasis on endemic and pandemic preparedness also fuel demand. Opportunities lie in emerging markets that are investing heavily in healthcare infrastructure and in novel vaccine technologies such as nucleic acid vaccines. Venturing into partnerships with biotech firms and increasing investments in flexible manufacturing technology could provide competitive advantages. However, challenges such as stringent regulatory environments, high initial capital investments, and ethical concerns over genetically modified organisms in vaccine production can impede growth.

Investment in automation and bioprocessing innovations represents potential areas for growth. Additionally, research into improving cold chain logistics and enhancing vaccine efficacy and safety profiles should be prioritized. The market is typified by rapid technological advancements and partnerships between entities aiming to leverage collective strengths. To seize potential opportunities, firms should focus on strategic alliances, horizontal expansion to diversify capabilities, and heavy investment in R&D to propel innovation. Hence, understanding regulatory landscapes and tailoring operations for each market are vital for sustained growth and competitive advantage in this dynamic landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccine Contract Manufacturing Market

The Vaccine Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing demand for vaccines leading to capacity expansion by contract manufacturers
  • Key advantages such as cost and time saving offered by contract services
  • Vaccination coverage across the globe
• Market Restraints
  • Limited outsourcing by well-established vaccine manufacturers
• Market Opportunities
  • Rising global demand to cater to the growing population of varied age groups
  • Innovation and robust vaccine pipeline
  • Favorable government insights and guidelines to speed up the vaccine manufacturing
• Market Challenges
  • Pharma companies manufacturing operations in-house to gain strategic control

Porter's Five Forces: A Strategic Tool for Navigating the Vaccine Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccine Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccine Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccine Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccine Contract Manufacturing Market

A detailed market share analysis in the Vaccine Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccine Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccine Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccine Contract Manufacturing Market

A strategic analysis of the Vaccine Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine, Subunit Vaccines, and Toxoid Vaccines.
• Based on Function, market is studied across Downstream and Upstream. The Downstream is further studied across Analytical & QC studies, Fill & Finish Operations, and Packaging. The Upstream is further studied across Bacterial Expression Systems, Baculovirus or Insect Expression Systems, Mammalian Expression Systems, and Yeast Expression Systems.
• Based on Application, market is studied across Human Use and Veterinary.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
    • 5.1.1.2. Key advantages such as cost and time saving offered by contract services
    • 5.1.1.3. Vaccination coverage across the globe
  • 5.1.2. Restraints
    • 5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising global demand to cater to the growing population of varied age groups
    • 5.1.3.2. Innovation and robust vaccine pipeline
    • 5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing adoption of attenuated vaccines to enhance immune systems
  • 5.2.2. Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
  • 5.2.3. Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Vaccine Contract Manufacturing Market, by Type

• 6.1. Introduction
• 6.2. Attenuated Vaccine
• 6.3. DNA Vaccines
• 6.4. Inactivated Vaccine
• 6.5. Subunit Vaccines
• 6.6. Toxoid Vaccines

7. Vaccine Contract Manufacturing Market, by Function

• 7.1. Introduction
• 7.2. Downstream
  • 7.2.1. Analytical & QC studies
  • 7.2.2. Fill & Finish Operations
  • 7.2.3. Packaging
• 7.3. Upstream
  • 7.3.1. Bacterial Expression Systems
  • 7.3.2. Baculovirus or Insect Expression Systems
  • 7.3.3. Mammalian Expression Systems
  • 7.3.4. Yeast Expression Systems

8. Vaccine Contract Manufacturing Market, by Application

• 8.1. Introduction
• 8.2. Human Use
• 8.3. Veterinary

9. Americas Vaccine Contract Manufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Vaccine Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
  • 12.3.2. Oxford Acquires ABL Europe From Institut Merieux For EUR 15 Mn
  • 12.3.3. Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc
• 2. Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc.
• 3. Aton (Shanghai) Biotech Co., Ltd.
• 4. Avid Bioservices, Inc.
• 5. Catalent, Inc.
• 6. Charles River Laboratories International, Inc.
• 7. CSL Limited
• 8. Curia Global, Inc.
• 9. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• 10. Emergent BioSolutions Inc.
• 11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
• 12. Gedeon Richter PLC
• 13. GlaxoSmithKline PLC
• 14. ICON PLC
• 15. IDT Biologika GmbH
• 16. KBI Biopharma, Inc. by JSR Corporation
• 17. Klocke Pharma-Service GmbH
• 18. Lonza Group Ltd.
• 19. Merck KGaA
• 20. Moderna, Inc.
• 21. Pfizer Inc.
• 22. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
• 23. Recipharm AB
• 24. Serum Institute of India
• 25. Vetter Pharma-Fertigung GmbH & Co. KG